TY - JOUR
T1 - Leadership decisions that shaped the destiny of Genzyme: Lessons from 30 years of entrepreneurial leadership: critical decisions for growth
AU - van der Steen, Marianne
AU - Englis-Danskin, Paula
PY - 2011
Y1 - 2011
N2 - This article is based on an interview of Marianne van der Steen with Henri Termeer‐the long time CEO of Genzyme. Within Europe, Genzyme’s state-of-the-art cell culture production facility for therapeutic proteins is located in Geel, Belgium, and is among the largest bio‐manufacturing sites in Europe. This month, the company announced that it will build an additional manufacturing plant in Geel.
The topic of the interview was growth decisions from biotech start-up to a fully integrated biopharma company. Henri Termeer, CEO, President and Chairman of Genzyme, looked back at 30 years of experience building a biopharma company. Henri talked about leadership decisions at the critical junctures of building a biopharma company. What are the lessons for European biotech entrepreneurs? How to breed European Gazelles?
AB - This article is based on an interview of Marianne van der Steen with Henri Termeer‐the long time CEO of Genzyme. Within Europe, Genzyme’s state-of-the-art cell culture production facility for therapeutic proteins is located in Geel, Belgium, and is among the largest bio‐manufacturing sites in Europe. This month, the company announced that it will build an additional manufacturing plant in Geel.
The topic of the interview was growth decisions from biotech start-up to a fully integrated biopharma company. Henri Termeer, CEO, President and Chairman of Genzyme, looked back at 30 years of experience building a biopharma company. Henri talked about leadership decisions at the critical junctures of building a biopharma company. What are the lessons for European biotech entrepreneurs? How to breed European Gazelles?
KW - IR-94067
KW - METIS-309018
M3 - Article
SP - -
JO - MIRA newsletter
JF - MIRA newsletter
ER -